Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind pegfilgrastim vs placebo for chemotherapy-induced neutropenia in breast cancer
jRCT2080221407Phase 3
- Sponsor
- Kyowa Kirin
- Start
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced neutropenia (CIN) and breast cancer comparing Pegfilgrastim (KRN125) with Placebo (2 arms).
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)breast cancer
Beyond the preview
Go deeper on jRCT2080221407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221407.